1. Scrip

Time For AI To Deliver In Drug Discovery, Says Atomwise CEO

 
• By Kevin Grogan

Having signed a multi-year, multi-target agreement with Lilly worth potentially $550m, Atomwise CEO Abe Heifets tells Scrip the burden of proof is on AI practitioners to start producing relevant and actionable data.

Data
Lilly signs AI pact with Atomwise • Source: Shutterstock

Eli Lilly & Co. is the latest big pharma to unveil a major artificial intelligence (AI) drug discovery collaboration after signing an agreement with one of the pioneers in the field, San Francisco-based Atomwise Inc..

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from AI

More from Digital Technologies